Latest Deals

The deal includes a $175m upfront payment for Roivant’s subsidiary Dermavant. Credit: testing / Shutterstock

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at close compared to their respective market opening prices on the day of the announcement. 

Novo Nordisk and NanoVation sign $600m deal

Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases. Novo has secured a licence to use NanoVation’s long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery targeting cells outside the liver. Both companies will collaborate on two programmes to develop base-editing therapies for rare genetic diseases, with plans for up to five future targets for cardiometabolic and rare diseases. 

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I

UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including respiratory syncytial virus (RSV) to Phase I trials. Vicebio is the latest biotech to eye up the RSV market, a space that has seen a buzz of development over the last year. Pharma giants GSK, Pfizer and Moderna have all brought vaccines for the illness to the market.

Source: Pharmaceutical Technology

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space

GC Therapeutics (GCTx) has propelled itself into the cell therapy space with $65m under its belt to deliver off-the-shelf induced pluripotent stem cell (iPSC)-based medicines. GCTx’s “plug and play” platform TFome – developed in the lab of Professor George Church at Harvard Medical School – transforms iPSCs into any cell type using a comprehensive collection of human transcription factors. 

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue